. Author manuscript; available in PMC: 2009 Jul 15.

Published in final edited form as: J Immunol. 2008 Jul 15;181(2):1345–1356. doi: 10.4049/jimmunol.181.2.1345

Table II.

Lymphoid DC subsets in the LRLN

	Treatment^b		L-Selectin^c		P₁^d	P₂^e Naive vs Treatment
DC Subset ^a	Ad2/βGal-2	LPS	−/−	+/+	−/− vs. +/+	−/−	+/ +
LRLN CD8⁺	–	–	14.4 ± 1.6	28.4 ± 3.6	0.004	-	-
“	+	–	16.7 ± 2.9	29.4 ± 3.1	0.006	NS	NS
“	+	+	31.7 ± 4.7	36.9 ± 4.3	NS	0.003	NS
LRLN CD8⁻	–	–	84.5 ± 1.6	71.0 ± 3.8	0.007	-	-
“	+	–	81.6 ± 2.8	69.6 ± 3.1	0.009	NS	NS
“	+	+	67.1 ± 5.0	61.8 ± 4.5	NS	0.004	NS

Pulmonary DCs were gated on lymphocytes that were CD11c ^low TCRαβ⁻.

DCs were derived from naive, Ad2/βGal-2-dosed, or Ad2/βGal-2 + LPS-dosed mice.

^−/− = L-Selectin-deficient mice; ^+/+ = B6 mice. Data presented as mean ± SEM.

p-value between L-Sel^−/− and L-Sel ^+/+ DC subsets (n = 10 mice/group); NS = not significant.

p-value between treatments within L-Sel^−/− or L-Sel ^+/+ groups.